Objective: Disturbances of the proteoglycan metabolism play an essential role in the pathology of osteoarthritis. The extracellular matrix proteoglycan, perlecan, has lately been identified as a cell biological factor in cartilage development and maintenance. We investigated the tissue distribution of perlecan, the relation between the level of the protein and its mRNA and which type of cell, type 1 chondrocytes or elongated secretory type 2 cells, produces perlecan in late stages of osteoarthritis.
Introduction
Articular cartilage is a highly specialized connective tissue, which covers the articulating ends of long bones 1 . The resilience, integrity and function of articular cartilage are guaranteed by the content and organization of the abundant extracellular matrix composed of a system of collagen fibrils in which a network of proteoglycans is embedded 2 . The chondrocytes, responsible for production, organization and maintenance of the extracellular matrix, constitute only 5e10% of the tissue volume and lack direct cellecell contacts 3, 4 . Normal adult hyaline cartilage contains types II, VI, IX, X and XI collagen, the greatest amount being collagen type II 5 . Collagen types II, IX and XI form fibrillar alloys with type XI as core and collagen type IX on the outside possibly limiting the fiber diameter 1, 6, 7 . The other important cornerstones of the extracellular matrix are the proteoglycans. They all consist of a core protein containing one or more glycosaminoglycan side chains 8 . With reference to the nature of their core proteins it is possible to allocate each proteoglycan to one of the several classes 9 , for example, large proteoglycans, such as aggrecan 10 and small proteoglycans such as fibromodulin, epiphycan, decorin and biglycan 9, 11, 12 .
Perlecan, as a new member of the proteoglycans found in cartilage 13 , is a large heparan sulfate proteoglycan present in all basement membranes 14 . It has been shown that perlecan is prominent in cartilage 9, 13 and is enriched mainly in the pericellular environment of the chondrocytes 15, 16 , suggesting a role in the attachment of chondrocytes to their own matrix 13 . The perlecan core protein is involved in the control of important biological functions such as cell adhesion 17 , maintenance of the extracellular matrix 18, 19 , binding to growth factors 20 , cartilage development 21 and regulation of chondrocyte differentiation 22 . The perlecan gene encodes an approximately 467 kDa protein core consisting of five distinct domains. The N-terminal domain I is unique to perlecan, whereas domains IIeV share sequence similarities with other cell surface and extracellular matrix proteins 23 . Domain I contains a cluster of three potential glycosaminoglycan attachment sites usually occupied by heparan sulfate side chains and may play an important role in chondrocyte differentiation and cartilage development 24 . Furthermore, mutations in perlecan lead to skeletal disorders. The relatively mild SchwartzeJampel syndrome as well as the neonatal lethal dyssegmental dysplasia of the SilvermaneHandmaker type show disorganization of the articular cartilage structure 15, 25 . Up to the present, nothing is known about the role of perlecan in osteoarthritis (OA), but important biological functions of this proteoglycan have already been established and it is possible that perlecan is involved in the pathophysiology of this disease. OA is an almost universal, slowly progressive degenerative process, which may take years to develop. The centre of the pathogenesis of OA is International Cartilage Repair Society a disturbed cellematrix relationship 26 . The primary lesion of the osteoarthritic process seems to be in the articular cartilage itself, i.e. to involve the chondrocytes and their surrounding matrix 27 . Further steps in the progress of this disease are the disruption of the matrix framework and the increasing water content followed by a loss of matrix strength 28 . A loss of the proteoglycans, aggrecan and decorin, collagen fiber fibrillation and surface splits occur in early stages of OA 26, 29 . An initially increased production of collagen type II has been detected only in early disease stages 30 . In contrast, late stages of OA show a mixture of reand degeneration processes 31, 32 . One indication of this is the occurrence of three main types of chondrocytes, which have been identified in osteoarthritic cartilage at the ultrastructural level 33 . Type 1 chondrocytes show a typical chondrocyte phenotype and may be arranged in clusters. These cells are mainly found in the macroscopically intact area of osteoarthritic cartilage. The elongated secretory type 2 cells, which have an irregular shape with a prominent rough endoplasmic reticulum, are mainly found in the deep zones of articular cartilage of the areas adjacent to the main defect. Degenerative type 3 cells are mainly found in the main defect itself and undergo degradation 33e35 . At the more advanced stages of OA, elongated secretory type 2 cells express collagens, such as collagen types I and III 32, 35 while the amounts of collagen type II are decreased 26 . The levels of transcription and translation for decorin and biglycan are also up-regulated in these cells 34 . Furthermore, fissures extending deep into the cartilage substance and cell cluster formation occur. These stages of disease are driven by degenerative processes catalyzed by tissue proteases 29, 36 , finally leading to the destruction of the articular cartilage with denudation of the subchondral bone 37 . In the present study, we investigated the levels of perlecan protein and mRNA and their distribution in the different chondrocyte cell types 33, 34 of late-stage osteoarthritic cartilage from human knee joints. For in vivo analysis, we performed light and electron microscopic immunohistochemistry and in situ hybridization, as well as real-time RT-PCR to quantitate the level of mRNA. Furthermore, we isolated the two cell types from osteoarthritic tissue taken from the patients and cultivated them separately. We also applied real-time RT-PCR to quantitate the level of mRNA produced by these two cell types in vitro.
Materials and methods

TISSUE SAMPLES
Adult osteoarthritic articular cartilage was obtained from the knee joints of 10 patients (age range 63e79 years) undergoing an operation for a total knee arthroplasty. Tissue specimens were collected from a region directly adjacent to the main defect and from a macroscopically intact region at the lateral border of the joint. The patients were suffering from late-stage OA and all met the American College of Rheumatology classification criteria 38 . Healthy control cartilage from a 50-year-old accident victim was also investigated. Patients gave their written informed consent according to the Ethics Regulations of the Medical Faculty of the Georg-August University Goettingen.
TISSUE PREPARATION AND SECTIONING
Specimens of articular cartilage were fixed in a formaldehyde solution, decalcified, dehydrated and finally embedded in paraffin for light microscopic investigations 39 . Afterwards, sections (4e5 mm) were cut and transferred onto slides. For topographical orientation and pathohistological grading, we stained the sections with Alcian blue and hematoxylineeosin (H.E.). For electron microscopy, we exclusively investigated specimens from the radial zone adjoining the tidemark. Tissue samples (1 mm 3 ) were cut and fixed for 15 min in 4% paraformaldehyde and 0.5% glutaraldehyde in phosphate-buffered saline (PBS) at 4(C. The tissue specimens were embedded in the hydrophilic resin LRGold Ò (London Resin Company, Reading, UK) as previously described 35 . Subsequently, ultrathin sections (80 nm) were cut and collected on formvar Ò coated nickel grids.
ANTIBODIES
Anti-DIG antibody (sheep IgG) was obtained from Quartett, Berlin, and an affinity-purified goat-anti-rabbit IgG from Medac, Hamburg. Each of them was coupled to 16 nm colloidal gold particles according to standard protocols 34 . Furthermore, we used an anti-DIG phosphataselabeled antibody from Roche Diagnostics, Heidelberg, for light microscopic in situ hybridization and a well-characterized, affinity-purified rabbit antibody against perlecan 17 .
LIGHT AND ELECTRON MICROSCOPIC IMMUNOHISTOCHEMISTRY
We performed the peroxidase anti-peroxidase (PAP) method with DAB substrate as described previously 39 and applied the primary antibody against perlecan diluted 1:50 in 1% BSA/PBS at RT for 15 h. For electron microscopic immunogold histochemistry, the goat-anti-rabbit IgG was labeled with gold particles as previously described 34, 35 . Ultrathin tissue sections were incubated with the antiperlecan antibody diluted 1:50 in PBS for 1 h at RT. The secondary gold-coupled antibody, diluted 1:300 in PBS, was applied for 20 min at RT. Staining with uranyl acetate followed and reactions were examined with the help of a Zeiss EM 906E electron microscope.
CONTROLS
For the PAP method, negative controls were performed by treating the sections with 1% PBS/BSA instead of the primary antibody and by carrying out only the DAB reaction. For the control for the immunogold histochemistry the tissue samples were incubated with pure gold solution in order to exclude unspecific binding of free colloidal gold. Furthermore, the reactions were performed with gold-coupled goatanti-rabbit IgG to exclude non-specific IgG binding.
STATISTICAL ANALYSIS
Micrographs of the two different cell types from all patients (n Z 10) were pooled. Mean values of the numbers of gold particles per cell (with S.E.M. ranging from 1 to 2) were analyzed in an area of 2000 nm 2 around 10 cells from each patient. Significant differences in the number of gold particles were noted for P-values (P % 0.001) using the WilcoxoneManneWhitney test for unpaired samples.
PROBE PREPARATION RNA was isolated as described below and reverse transcribed into perlecan-specific cDNA. PCR was performed with primers specific for perlecan and a T3-promoter sequence 5#-CAG AGA TGC AAT TAA CCC TCA CTA AAG GGC TCG GGG CGA ACT GAT GGT A-3# (a reverse primer) and a T7-promoter sequence 5#-CCA AGC TTC TAA TAC GAC TCA CTA TAG GGA CCT TCG CTG GCT CAA GGA G-3# (a forward primer) to insert the promoter sequences. Afterwards, in vitro transcription of non-radioactive sense and antisense RNAs with a digoxigenin labeling kit (Boehringer DIG-RNA labeling kit, Boehringer, Mannheim, Germany) was performed applying the T3-and T7-polymerases (Gibco/BRL, Heidelberg, Germany). Following extraction of the probes with phenole chloroform these were precipitated with absolute ethanol and dissolved in DEPCeH 2 O.
LIGHT AND ELECTRON MICROSCOPIC IN SITU HYBRIDIZATION
For light microscopic investigations, paraffin sections were deparaffinized, rehydrated and pre-treated with proteinase K. For the hybridization, the probe concentration was 100 ng digoxigenin-labeled antisense probe for perlecan in 100 ml hybridization solution (50% formamide, 5! SSC, 0.1 mg/ml yeast-RNA, 10 ng/ml probe) for each section. Hybridization was carried out for 16 h at 50(C. Posthybridization treatment included a washing procedure with 4! SSC (3 ! 10 min, at 50(C), 2! SSC (1 ! 15 min, at 60(C), 0.1! SSC (1 ! 15 min, at 60(C) and 0.05! SSC (1 ! 15 min, at 60(C). Afterwards the incubation with the anti-DIG phosphatase-labeled antibody diluted 1:300 in PBS was started. Finally color reactions were started with NBT/BCIP substrate. For electron microscopy, nickel grids were incubated with the same hybridization solution as described above for 19 h at 50(C. Probe concentration for perlecan was 100 ng digoxigenin-labeled antisense probe in 20 ml hybridization solution per grid. Rinsing steps were the same as described above. Afterwards, sections were incubated with the gold-coupled anti-DIG antibody in PBS (diluted 1:60) for 1 h at RT. The specimens were rinsed with PBS, contrasted and analyzed with the Zeiss EM 906E.
CONTROLS
Each hybridization was accompanied by a hybridization with an equivalently labeled amount of sense probe. Furthermore, hybridizations were performed without any RNA probes. Additionally, for the ultrastructural controls, tissue sections were treated with pure gold solution or the coupled anti-DIG antibody alone.
STATISTICAL ANALYSIS
For in situ hybridization at the ultrastructural level, micrographs of the two different cell types from patients (n Z 6) were pooled and counted for gold particle contents. Mean values of the numbers of gold particles per cell (with S.E.M. ranging from 1 to 3) were analyzed in an area of 2000 nm 2 in 10 cells from each patient. Significant differences in the number of gold particles were noted for P-values (P % 0.01) using the WilcoxoneManneWhitney test for unpaired samples.
CELL CULTURE Two 0.5 cm 3 pieces of osteoarthritic cartilage tissue, one from an area adjacent to the main defect and one from a macroscopically intact area, from each of the four patients were minced and cells were isolated by treatment with collagenase type II (2 mg/ml, Sigma) in DMEM-F12 medium supplemented with 20% FSC and 100 mmol ascorbic acid overnight at 37(C and 5% CO 2 . Thereafter, the suspension was centrifuged and the cells transferred to culture flasks coated with fibronectin in PBS (0.01 mg/25 cm 2 ). After a 10 h incubation period, the supernatant containing the type 1 chondrocytes was decanted into a new flask, while the elongated secretory type 2 cells already attached to the substratum remained in the first flask. After approximately For the extraction of RNA from the native tissue, three cartilage tissue samples, each approximately 20 mg wet weight, were taken from each of three patients from the area adjacent to the main defect and from a macroscopically intact region at the lateral border of the joint and were frozen in liquid nitrogen, pulverised with a mortar and pestle, mixed in TRIZOL Ò (Biozol, Germany) and incubated for 10 min at RT. After a centrifugation step the aqueous phase was transferred to an RNAeasy Mini-column (RNAeasy Mini Kit, Qiagen) and processed according to the manufacturer's instructions.
RNA EXTRACTION FROM CULTURED CELLS AND RT
RNA from the cultured cells was isolated according to the manufacturer's instructions (RNAeasy Mini Kit, Qiagen); all RNA populations were treated with DNAfree Ò (Ambion) and reverse transcribed with the help of the Advantage RT-for-PCR Kit (BD Bioscience) applying MMLV reverse transcriptase and oligo(dT) 18 primer. PCR PCR conditions were optimized by applying the gradient function of the DNA engine Opticon 2 (MJ Research) for HPRT-1 (NM_000194) 40, 41 and, for perlecan (M85289), primers ( forward TCA GTC CCT TGT CAC CAT CCA, reverse TAA GCT GCC TCC ACG CTT AT) to amplify a 180 bp transcript were designed by the primer3 Ò shareware. HPRT-1 was chosen as house-keeping gene because it has been described as being unregulated in many instances 40, 41 and was proved to be unregulated particularly in our experimental setting. The PCR was performed in a total volume of 50 ml with 200 ng cDNA derived from the type 1 chondrocytes or the elongated secretory type 2 cells, 5 ml 10! reaction buffer, dNTP 
REAL-TIME PCR
In order to optimize the real-time PCR conditions for quantification, the optimal MgCl 2 concentration was determined. A total of 12.25 ml of 2! QuantiTect SYBR Green PCR Master Mix (Qiagen), 20 pmol of each primer and 250 ng of cDNA were added to a final volume of 25 ml. Cycling was performed following the protocol described above. Data acquisition was carried out after each extension step and a melting curve was performed in 0.1(C steps from 50(C to 95(C. Real-time PCR efficiencies were calculated from the given slopes in Opticon 2 Monitor software 42 . Real-time PCR efficiency rates were high with values of 1.97. Experiments were performed four times in triplicate; the inter-test variation was %2.5% and the intra-test variation %1.2%. One PCR product was purified and sequenced to confirm that the nucleotide sequence was that of perlecan.
Results
PATIENT DATA
Macroscopically, all tissue samples from the patients revealed advanced OA with sclerosis and joint space narrowing (Fig. 1) . Pathohistologically they could be classified as OA grades IIIeIV 43 . All patients suffered from load or rest-pain of the knee. No obvious correlation between age, sex, weight, height, or clinical condition was detectable (Table I) .
LIGHT MICROSCOPIC HISTOLOGY
The physiological normal control cartilage sections, obtained from a 50-year-old male accident victim, revealed a homogeneously stained matrix and a normal structure of articular cartilage following H.E. [ Fig. 2(A) ] and Alcian blue staining [ Fig. 2(D) ]. The specimens taken from the macroscopically intact cartilage areas of the patients with late-stage OA exhibited an increased number of cells, i.e. diffuse hypercellularity, and a small number of cells arranged in clusters [ Fig. 2(B) ]. Furthermore, reduced Alcian blue staining, indicating a loss of glycosaminoglycans, was detected [ Fig. 2(E) ]. The tissue samples from the area adjacent to the main defect revealed fissured cartilage tissue, an increased number of clusters [ Fig. 2(C) ] and reduced staining for Alcian blue [ Fig. 2(F) ].
LIGHT AND ELECTRON MICROSCOPIC IMMUNOHISTOCHEMISTRY
Light microscopic immunohistochemistry of the cartilage tissues revealed mainly pericellular staining for perlecan in all samples investigated. Specimens taken from the macroscopically intact areas [ Fig. 3(A) ] or from the healthy control cartilage (data not shown) showed strong staining in the pericellular matrix of the radial zone and weaker staining in the transitional zone. In contrast to the two zones described above, no staining for perlecan was detected in the superficial layer of articular cartilage. Furthermore, specimens taken from the area adjacent to the main defect revealed staining for the perlecan protein also in the interterritorial matrix and exhibited a more intense staining for perlecan than the specimens from the macroscopically Fig. 3(B) ]. Due to difficulties involved in differentiation between type 1 and type 2 cells at the light microscopic level we performed investigations at the ultrastructural level. Ultrastructurally, the macroscopically intact areas revealed chondrocytes of normal phenotype with sparse, finely structured endoplasmic reticulum. These type 1 cells with numerous filopodia were embedded in a homogeneous extracellular matrix with collagen fibers and proteoglycans [ Fig. 4(A) ]. The area adjacent to the main defect showed irregular, elongated cells containing large amounts of a prominent and enlarged rough endoplasmic reticulum [ Fig. 4(B) ] and was classified as elongated secretory type 2 cells 33, 34 . In agreement with the results from the light microscopic immunohistochemistry we detected higher perlecan protein amounts at the ultrastructural level in the interterritorial matrix of the cartilage tissue samples taken from the area adjacent to the main defect where perlecan was found close to thin collagen fibers [ Fig. 4(C) ]. Similarly, immunogold histochemistry revealed staining for perlecan mainly in the extracellular matrix which directly surrounds the chondrocytes, i.e. the pericellular matrix, for type 1 cells Quantitation of the results of the ultrastructural in situ hybridization revealed an approximately 45% higher amount of perlecan mRNA in the elongated secretory type 2 cells than in the type 1 cells with P-values %0.01 [ Fig. 6(B) ]. 
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CONTROLS
The control hybridizations performed with a sense probe or without any RNA probe revealed no reaction. Ultrastructural control hybridizations were carried out with a sense probe and exhibited a sparse labeling which could be regarded as unspecific background. Treatment of sections with pure gold solution as well as with gold-coupled anti-DIG antibody produced no reaction.
RT-PCR AND REAL-TIME PCR
We isolated the cartilage cells from an area adjacent to the main defect and from a macroscopically intact area and were able to separate the two cell types detected in vivo by their kinetics of adherence to the fibronectin substratum of the culture flask 44 . The elongated secretory type 2 cells adhered already after 10 h, while the type 1 chondrocytes needed at least 24 h for attachment. Therefore, we were able to culture type 1 and type 2 cells separately. When near confluence was reached in the first passage, we harvested the cells and isolated the RNA. RT-PCR detected a slightly thicker band for the perlecan mRNA in type 2 cells (Fig. 7, lane 2) as compared to the type 1 cells (Fig. 7, lane 1) . We also performed quantitative real-time RT-PCR and were first able to determine an unregulated housekeeping gene 40, 41 , HPRT-1, with identical ct values of approximately 24, i.e. the same amounts of transcripts for Fig. 8(B) ] and by sequencing the perlecan product (data not shown). Real-time PCR of the native cartilage tissue taken from the area adjacent to the main cartilage defect revealed mean ct values of 28.0 and from a macroscopically intact area of 30.1 [ Fig. 8(C) ]. This demonstrates a 50% higher level of perlecan mRNA in the area adjacent to the main cartilage defect taken from native tissue.
Discussion
According to a well-established grading system, our specimens were pathohistologically graded and were all found to be grades IIIeIV, i.e. late stages of OA 43 . The osteoarthritic cartilage samples from patients investigated here showed signs of degeneration and to a lesser extent of regeneration. As OA is based on multifactorial conditions with a complex pathogenesis 26e38,43 , it is very difficult to achieve a clear histological demarcation between degenerative and regenerative changes. For electron microscopic immunohistochemistry and ultrastructural in situ hybridization, we exclusively investigated the deep zones of osteoarthritic cartilage, i.e. samples from the deep zones of a macroscopically intact area and an area adjacent to the main defect. In this region, where the main regeneration processes take place, we saw mainly elongated secretory type 2 cells described several years ago as a sign of the regeneration efforts of the diseased cartilage tissue 31,33e35 . In the present study, we investigated the role of the proteoglycan perlecan in human knee joint cartilage from patients suffering from late-stage OA. It is well known that proteoglycans such as aggrecan, biglycan and decorin are involved in the pathophysiology of OA 26e29 . A loss of decorin and biglycan was described for the superficial layers of osteoarthritic cartilage 29 , while an increased amount of these proteoglycans, as well as an increased transcription rate, was detected in the deeper zones of osteoarthritic cartilage. In spite of the overall proteoglycan loss due to the reduction of the major matrix component aggrecan in late-stage OA, we also detected increasing amounts of mRNA of decorin and biglycan in the deep zones of OA cartilage. Especially the elongated secretory type 2 cells occurring in late-stage OA revealed an up-regulated expression of these proteoglycans 34 . Our present in vivo analysis at the light and electron microscopic level revealed a tissue distribution for perlecan in late stages of OA similar to that described for physiological cartilage 13, 15, 16 . Perlecan was mainly found in the deeper zones of the cartilage and in cell clusters of late stages of OA. In contrast to normal cartilage, the tissue samples taken from the area adjacent to the main defect also revealed staining for perlecan in the interterritorial matrix, where it was mainly found on fine collagen fibers. Perlecan knockout mice exhibited reduced amounts of collagen fibers and a lack of the typical collagen network 19 suggesting an important role of this proteoglycan in maintaining the collagen network in articular cartilage. Thus, one might assume that the increased levels of perlecan protein in late stages of OA can be seen as an effort on the part of the cartilage tissue to stabilize the extracellular matrix and the collagen fibers embedded in it. Ultrastructural analysis revealed an approximately 45% higher mRNA level for perlecan in late stages of OA. Similar observations have been made for the mRNA levels of the two small proteoglycans decorin and biglycan in late stages of OA 34 . The increase in the level of perlecan protein and mRNA is achieved by the elongated secretory type 2 cells and these cells deposit perlecan mainly in the pericellular matrix. This was confirmed by a 50% increase of perlecan mRNA in vivo taken from native cartilage and in vitro taken from cultured cells as shown by quantitative real-time RT-PCR. With regard to the enhanced level of perlecan protein around chondrocyte clusters adjacent to the cells in the pericellular matrix, it remains to be seen whether perlecan shows any mitogenic activity in these late disease stages. The glycosaminoglycan side chains of perlecan act as a low-affinity co-receptor for FGFs and mitogenic activity has already been shown for other cells 20 . The type 2 cells which are the only new cells emerging at late stages of OA and the ones mainly responsible for the regeneration processes of cartilage matrix 33, 34 produce more perlecan, which might be beneficial for the matrix integrity and the chondrocytes embedded in it. In normal cartilage, perlecan interacts with other adhesive extracellular macromolecules to stabilize the matrix and to enable the adhesion of chondrocytes to their own substratum 13, 18, 19 . The role of collagen type IX, which also shows characteristics of a proteoglycan, for the structural integrity of the pericellular matrix has been underlined 3 . In late stages of OA the integrity of the pericellular matrix is altered and it would be interesting to investigate whether the increased amounts of perlecan shown here can help to stabilize the pericellular matrix. The increased amount of perlecan protein, especially in the area next to the main defect, may be seen as an effort on the part of the cartilage tissue to compensate for the rapid loss of other matrix molecules such as aggrecan 29 . In conclusion, the results presented here indicate the involvement of perlecan in the pathogenesis of late stages of OA. The higher level of perlecan mRNA especially in the elongated secretory type 2 cells mainly found in the areas adjacent to the main cartilage defect and the increased level of perlecan protein mainly deposited in the pericellular matrix and to a lesser extent in the interterritorial matrix, might reflect an attempt on the part of the cartilage tissue to stabilize and protect the remaining matrix of late-stage osteoarthritic cartilage from further destruction. 
